Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 30Terminated 12Recruiting 9Active not recruiting 4Withdrawn 3Unknown 2Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 9Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Triple Negative Breast Neoplasms 1Neoplasms, Plasma Cell 1Malignant Plasma Cell Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Plasma Cell 1Infections 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 3Cyclophosphamide 3obinutuzumab 2fludarabine 2daratumumab 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Dexamethasone 2Bortezomib 2Biopsy 2Bendamustine Hydrochloride 2zanubrutinib 1venetoclax 1tafasitamab 1selinexor 1prednylidene 1polatuzumab vedotin 1pegaspargase 1orelabrutinib 1nelarabine 1merphos 1glofitamab 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1calaspargase pegol 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma × Lenalidomide × Clear all
NCT06549335 2024-10-15

Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

Ruijin Hospital

Phase 2 Not yet recruiting
66 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡